Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies

[1]  Siddharth Singh,et al.  Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium , 2018, The American Journal of Gastroenterology.

[2]  M. Murad,et al.  Systematic review with network meta‐analysis: first‐ and second‐line pharmacotherapy for moderate‐severe ulcerative colitis , 2018, Alimentary pharmacology & therapeutics.

[3]  D. Hommes,et al.  Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial , 2017, The Lancet.

[4]  I. Dotan,et al.  Comparative Study of Two Cohorts of Newly Diagnosed Crohn's Disease Demonstrates Change in Therapeutic Strategies , 2017, Digestion.

[5]  L. Peyrin-Biroulet,et al.  Ulcerative colitis , 2017, The Lancet.

[6]  L. Peyrin-Biroulet,et al.  Crohn's disease , 2017, The Lancet.

[7]  S. Bonovas,et al.  The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar , 2017, Inflammatory bowel diseases.

[8]  P. Rutgeerts,et al.  The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.

[9]  L. Peyrin-Biroulet,et al.  Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. , 2017, Gastroenterology.

[10]  Abhijeet Yadav,et al.  Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease. , 2017, Inflammatory bowel diseases.

[11]  M. Dubinsky,et al.  Gastroenterologists’ Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey , 2016, Advances in Therapy.

[12]  John T. Chang,et al.  The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, The American Journal of Gastroenterology.

[13]  T. Wyant,et al.  An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. , 2016, Journal of Crohn's & colitis.

[14]  M. Regueiro,et al.  Ulcerative Colitis Care Pathway. , 2015, Gastroenterology.

[15]  W. Sandborn.  Crohn's disease evaluation and treatment: clinical decision tool. , 2014, Gastroenterology.

[16]  D. Hommes,et al.  Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. , 2013, Journal of Crohn's & colitis.

[17]  D. Rubin,et al.  Response to biologic therapy in Crohn's disease is improved with early treatment: An analysis of health claims data , 2012, Inflammatory bowel diseases.

[18]  P. Rutgeerts,et al.  Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease , 2008, Alimentary pharmacology & therapeutics.

[19]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[20]  W. Tremaine,et al.  American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[21]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.

[22]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.